Nectin-4-Targeted Immunotherapy Pipeline Review
Target: Nectin-4; Nectin cell adhesion molecule-4
Product Category: Antibody; Peptide; Cells
This product provides basic information on immunotherapeutics on the market and in R&D targeting nectin-4.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting nectin-4 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The cell surface adhesion protein Nectin-4 is a cancer associated antigen over-expressed in many solid tumor types with limited expression in normal tissues. Nectin-4 is closely related to the progression and poor prognosis of malignant tumors.
Enfortumab Vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate approved by the US FDA for the treatment of advanced urothelial carcinoma. Thereby, nectin-4 has become a clinically validated and commercially successful cancer target. However, inadequate efficacy has limited progress in the treatment of other solid tumors with EV. Furthermore, side effects caused by EV frequently result in dose reduction and/or treatment termination.
Thus, the limitations of EV provides a window of opportunity for novel drug modalities targeting nectin-4 with the promise to improve efficacy and safety.